New Ipo 2024 Review. Deloitte china's capital market services group (cmsg) today released its analysis of the performance of chinese mainland and hong kong initial public offering. After two years in which high interest rates and eroded tech valuations curtailed ipo activity, technology and healthcare companies, especially those leveraging.
Join our panel of market experts as they review equity issuance from the first half of 2024, with a deep dive into ipo performance, the deal pipeline, and industry. No matter what kind of investor you are, our ipo reviews will help you understand the pros & cons of the company, along with the possible risks and rewards related to investing.
